555P TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial

Abstract

The treatment options after first-line chemotherapy for endometrial cancer (EC) are very limited. There is a substantial need for second line and subsequent treatment of advanced EC. Several immune checkpoint inhibitors or combined with antiangiogenic drugs have shown antitumor activity and been approved in EC. Anlotinib is a multiple-targeted tyrosine kinase inhibitor that has been approved for the treatment of several solid tumors. TQB2450 is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1).